Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation

Soyon Hong
Harvard University

Omar Quintero-Monzon
Harvard University

Beth L. Ostaszewski
Harvard University

Daniel R. Podlisny
Harvard University

William T. Cavanaugh
Harvard University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Part of the Medicine and Health Sciences Commons

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/683
Neurobiology of Disease

Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation

Soyon Hong,1 Omar Quintero-Monzon,1 Beth L. Ostaszewski,1 Daniel R. Podlisny,1 William T. Cavanaugh,1 Ting Yang,1 David M. Holtzman,2 John R. Cirrito,2 and Dennis J. Selkoe1

1Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, and 2Department of Neurology, Developmental Biology, Hope Center for Neurological Disorders, Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110

Growing evidence supports the hypothesis that soluble, diffusible forms of the amyloid β-peptide (Aβ) are pathogenically important in Alzheimer’s disease (AD) and thus have both diagnostic and therapeutic salience. To learn more about the dynamics of soluble Aβ economy in vivo, we used microdialysis to sample the brain interstitial fluid (ISF), which contains the most soluble Aβ species in brain at steady state, in >40 wake, behaving APP transgenic mice before and during the process of Aβ plaque formation (age 3–28 months). Diffusible forms of Aβ, especially Aβ42, declined significantly in ISF as mice underwent progressive parenchymal deposition of Aβ. Moreover, radiolabeled Aβ administered at physiological concentrations into ISF revealed a striking difference in the fate of soluble Aβ in plaque-rich (vs plaque-free) mice: it clears more rapidly from the ISF and becomes more associated with the TBS-extractable pool, suggesting that cerebral amyloid deposits can rapidly sequester soluble Aβ from the ISF. Likewise, acute γ-secretase inhibition in plaque-free mice showed a marked decline of Aβ1–40, Aβ1–42, and Aβ42, whereas in plaque-rich mice, Aβ42 declined significantly less. These results suggest that most of the Aβ42 that populates the ISF in plaque-rich mice is derived not from new Aβ biosynthesis but rather from the large reservoir of less soluble Aβ42 in brain parenchyma. Together, these and other findings herein illuminate the in vivo dynamics of soluble Aβ during the development of AD-type neuropathology and after γ-secretase inhibition and help explain the apparent paradox that CSF Aβ42 levels fall as humans develop AD.

Introduction

After decades of investigative focus on amyloid plaques in Alzheimer’s disease (AD), recent findings have led to a conceptual shift. Emerging evidence suggests that the insoluble amyloid fibrils that comprise plaques may not directly confer neurotoxicity but sequester small, diffusible assemblies of amyloid β-peptide (Aβ) that have been shown to potentiate alter synaptic structure and function (Walsh and Selkoe, 2007). The recognition of Aβ oligomers as highly bioactive assemblies has furthered interest in detecting and analyzing soluble forms of the peptide for mechanistic, diagnostic, and therapeutic purposes. Although factors other than Aβ dyshomeostasis contribute importantly to the pathogenesis of AD (Pimplikar et al., 2010), virtually all potentially disease-modifying treatments currently under development are focused on decreasing or neutralizing this neurotoxic peptide. Moreover, a reduced CSF level of Aβ42 in subjects with incipient or very early AD is one of the most promising biomarkers. Despite this therapeutic and diagnostic focus, we still lack insight into the in vivo economy of the most soluble forms of Aβ in the brain during the development of AD-type pathology.

Here, we used brain microdialysis in awake and behaving hAPP transgenic (tg) mice to gain an understanding of Aβ dynamics before and during the process of Aβ plaque formation. Brain interstitial fluid (ISF) contains the Aβ pool that best reflects the physiological secretion and fate of soluble species. Microdialysis in mouse models of AD and even human subjects is providing important insights into the dynamics of normal ISF Aβ economy (Brody et al., 2008; Cirrito et al., 2008; Kang et al., 2009) and may help identify the earliest, most subtle Aβ changes that occur as AD-type neuropathology begins. Given the power of this in vivo sampling method, we performed hippocampal microdialysis on >40 freely moving APP transgenic mice of increasing age as a model of cerebral Aβ accumulation, and we searched for changes in the quality and quantity of Aβ species as the brain
accretes insoluble deposits and undergoes neuronal and glial injury. We systematically analyzed the nature of endogenous Aβ over time using sensitive sandwich ELISAs, immunoprecipitation (IP)/Western blotting (WB), native and denaturing PAGE, and size exclusion chromatography (SEC). We then complemented these analyses by assessing the fate of radiolabeled Aβ microinjected at physiological concentrations as a surrogate of newly secreted Aβ, and the results help explain the fall of Aβ$_{42}$ in the CSF of humans with AD. Together, these experiments describe the in vivo dynamics of the most soluble pool of brain Aβ during the process of AD-type amyloid plaque formation.

**Materials and Methods**

**Mice.** J20 line carrying hAPP minigene with FAD mutations KM670/671NL and V717F (a kind gift from L. Mucke, Gladstone Institute, University of California San Francisco, San Francisco, CA) was maintained on a C57BL/6 × DBA2 background (Mucke et al., 2000). All animal procedures were approved by the Harvard Medical School Institutional Animal Care and Use Committee. Mice of both sexes were used in all experiments.

In vivo Aβ microdialysis. Microdialysis was performed as previously described (Cirrito et al., 2003): intracerebral guides were inserted following the coordinates for left hippocampal placement (bregma: −3.5 mm, 2.5 mm lateral to midline, and 1.2 mm below dura at 12° angle). Perfusion buffer (1.5% bovine serum albumin in artificial CSF [in mM: 1.3 CaCl$_2$, 1.2 MgSO$_4$, 3 KCl, 0.4 KH$_2$PO$_4$, 25 NaHCO$_3$, and 122 NaCl, pH 7.35]) was perfused using probes with 35 kDa molecular weight cutoff (MWCO) membranes (BR-2; Bioanalytical Systems) at flow rates 0.2–1 µl/min. Aβ$_{40}$ and Aβ$_{42}$ in ISF were kept on 12 h light/dark cycles, and housed in a Raturn cage system (SHIBU). Mice were sectioned at 8 µm thickness, as previously described (Lemere et al., 2002). R1282 polycyonal antibody was used to stain Aβ and the immunoreactivity was visualized using the Vector Elite horseradish–peroxi-dase ABC kit (Vector Laboratories) with diaminobenzidine (Sigma) as the chromogen.

**In vivo microdialysis.** Mouse brains of 3- and 24-month-old tg mice and wt littermates were homogenized in 1% (v/v) Nonidet P-40 STEN buffer (in mM: 150 NaCl, 50 Tris, 2 EDTA) using a Teflon Dounce homogenizer. Brain lysates were loaded onto 4–12% Bis-Tris gel, electrophoresed with SDS running buffer, transferred onto 0.2 µm nitrocellulose, then blotted with polyclonal antibody C7 (to full-length APP and its C-terminal fragments) and anti-α-tubulin polyclonal antibody (Thermo Scientific).

**Size-exclusion chromatography.** TBS extracts (250 µl) or synthetic Aβ (2 ng) were eluted at 0.5 ml/min from a Superdex 200 10/300GL column (GE Healthcare) with 50 mM ammonium acetate, pH 8.5. Resulting 1 ml fractions were eluted, reconstituted in LDS sample buffer, and heated at 65°C for 10 min. Samples were subjected to WB using 3D6 (to Aβ$_{1–40}$ Covance) and 4G8, and visualized using the LiCor Odyssey Infrared Imaging System. For bicine/urea-based SDS-PAGE, a previously described protocol (Klafki et al., 1996) was modified. Briefly, ISF was captured compared with the theoretical (Aβ) at zero PR.

**Immunoprecipitation and Western blot for Aβ.** ISF Aβ$_{40}$ and Aβ$_{42}$ were eluted at 0.5 ml/min from a Superdex 200 10/300GL column (GE Healthcare) with 50 mM ammonium acetate, pH 8.5. Resulting 1 ml fractions were eluted, reconstituted in LDS sample buffer, and heated at 65°C for 10 min. Samples were subjected to WB using 3D6 (to Aβ$_{1–40}$) and visualized using the LiCor Odyssey Infrared Imaging System or ECL Plus WB Detection Reagent (GE Healthcare).

**Immunohistochemistry of brain sections.** 120 APP tg brains at ages 3, 12, and 24 months were fixed with 10% formalin, paraffin-embedded, then sectioned at 8 µm thickness, as previously described (Lemere et al., 2002). R1282 polyclonal antibody was used to stain Aβ and the immunoreactivity was visualized using the Vector Elite horseradish–peroxi-dase ABC kit (Vector Laboratories) with diaminobenzidine (Sigma) as the chromogen.

**Materials and Methods.**

**Mice.** J20 line carrying hAPP minigene with FAD mutations KM670/671NL and V717F (a kind gift from L. Mucke, Gladstone Institute, University of California San Francisco, San Francisco, CA) was maintained on a C57BL/6 × DBA2 background (Mucke et al., 2000). All animal procedures were approved by the Harvard Medical School Institutional Animal Care and Use Committee. Mice of both sexes were used in all experiments.

In vivo Aβ microdialysis. Microdialysis was performed as previously described (Cirrito et al., 2003): intracerebral guides were inserted following the coordinates for left hippocampal placement (bregma: −3.5 mm, 2.5 mm lateral to midline, and 1.2 mm below dura at 12° angle). Perfusion buffer (1.5% bovine serum albumin in artificial CSF [in mM: 1.3 CaCl$_2$, 1.2 MgSO$_4$, 3 KCl, 0.4 KH$_2$PO$_4$, 25 NaHCO$_3$, and 122 NaCl, pH 7.35]) was perfused using probes with 35 kDa molecular weight cutoff (MWCO) membranes (BR-2; Bioanalytical Systems) at flow rates 0.2–1 µl/min. Aβ$_{40}$ and Aβ$_{42}$ in ISF were kept on 12 h light/dark cycles, and housed in a Raturn cage system (SHIBU). Mice were sectioned at 8 µm thickness, as previously described (Lemere et al., 2002). R1282 polyclonal antibody was used to stain Aβ and the immunoreactivity was visualized using the Vector Elite horseradish–peroxi-dase ABC kit (Vector Laboratories) with diaminobenzidine (Sigma) as the chromogen.

**In vivo microdialysis.** Mouse brains of 3- and 24-month-old tg mice and wt littermates were homogenized in 1% (v/v) Nonidet P-40 STEN buffer (in mM: 150 NaCl, 50 Tris, 2 EDTA) using a Teflon Dounce homogenizer. Brain lysates were loaded onto 4–12% Bis-Tris gel, electrophoresed with SDS running buffer, transferred onto 0.2 µm nitrocellulose, then blotted with polyclonal antibody C7 (to full-length APP and its C-terminal fragments) and anti-α-tubulin polyclonal antibody (Thermo Scientific).

**Size-exclusion chromatography.** TBS extracts (250 µl) or synthetic Aβ (2 ng) were eluted at 0.5 ml/min from a Superdex 200 10/300GL column (GE Healthcare) with 50 mM ammonium acetate, pH 8.5. Resulting 1 ml fractions were eluted, reconstituted in LDS sample buffer, and heated at 65°C for 10 min. Samples were subjected to WB using 3D6 (to Aβ$_{1–40}$) and visualized using the LiCor Odyssey Infrared Imaging System or ECL Plus WB Detection Reagent (GE Healthcare).

**Compound E treatment.** Compound E (3 mg/kg; Axxonra) was injected intraperitoneally to mice undergoing microdialysis. Half-lives were calculated according to Cirrito et al. (2003).

**Radioactivity assay.** For ISF experiments, 3 µl of 1 nM [125I]-β-amyloid (1–40) (PerkinElmer) was injected into a combination infusion cannula and microdialysis probe (IBR-2; Bioanalytical Systems) at 0.2 µl/min. ISF was collected hourly at 0.6 µl/min, paused during the injection, then restarted 1 min after injection. For TBS extractions, 5 µl of [125I]-β-amyloid (1–40) were injected in paired mice (young and old). Brains were harvested for TBS extract preparation 1.5 h postinjection. [125I] levels were counted using a LS6500 multipurpose scintillation counter (8 min counts).

**Clear native PAGE and subsequent denaturation for SDS-PAGE.** TBS extracts were prepared from homogenized brains of 24-month-old tg mice and wt littermates, then subjected to non-denaturing clear native PAGE, which separates proteins with isoelectric point <7 based on their intrinsic charge (Wittig and Schägger, 2005). Briefly, samples were electrophoresed using native PAGE 4–16% Bis-Tris gel (Invitrogen) with Bis-Tris-HCl, pH 7.0, as anode and Tricine Bis-Tris, pH 7.0, as cathode buffers. Proteins were then transferred onto 0.2 µm PVDF (Millipore), boiled and blotted for Aβ using monoclonal antibodies 2G3 and 21F12 (to Aβ$_{1–40}$ Covance). The blotted gels were heated to 100°C in denaturing LDS sample buffer and supernatants were electrophoresed using 12% Bis-Tris gel and MES SDS running buffer (Invitrogen) for Western blotting.
Results

Biochemical analysis of Aβ peptides that remain soluble in the brains of young, behaving hAPP transgenic mice

To examine the quantity and quality of Aβ that remains soluble and of low molecular weight in ISF in vivo (termed ISF Aβ herein), we used a microdialysis probe with a 35 kDa MWCO membrane in mice expressing FAD-mutant human APP [J20 line (Mucke et al., 2000)]. When we intraperitoneally injected Compound E, a potent and brain-penetrant γ-secretase inhibitor (Grimwood et al., 2005; Yan et al., 2009), total ISF Aβ captured in microdialysates fell rapidly (t1/2 ~ 2 h) to baseline (Fig. 1a), showing that most of the ISF Aβ we sampled by microdialysis in young mice represents newly synthesized APP cleavage products. To capture the Aβ species that best reflect the physiological levels, we performed microdialysis at a slow perfusion rate of 0.2 μl/min for up to 72 h, as this allows optimal exchange of free Aβ into the probe. ISF samples were immunoprecipitated with a polyclonal Aβ antiserum (AW8), and the precipitates were separated by denaturing PAGE and blotted with pooled monoclonal antibodies to the N terminus (6E10) and midregion (4G8) of Aβ. The ISF Aβ was separated by conventional SDS-PAGE into two species: a 4 kDa monomer and a novel ~5 kDa species, which ran approximately half the time as a band (Fig. 1b) and the other half as a smear (Fig. 4a). We did not detect dimers (which run at ~6.5 kDa in these gels; Fig. 1b) by IP/WB in the ISF of any of the >40 mice we examined in this study, regardless of age. In vitro (test tube) microdialysis of synthetic Aβ40 showed that our 35 kDa MWCO membrane allowed passage of dimers; however, their diffusion efficiency was low compared with that of monomers (data not shown), suggesting that the lack of dimers in the ISF samples could be due to the detection limit of the technique. Next, we analyzed the mouse ISF by bicine/urea SDS-PAGE, which electrophoretically separates Aβ peptides of different lengths (Klafka et al., 1996). ISF Aβ was resolved into three principal bands comigrating with synthetic Aβ1−39, Aβ1−40, and Aβ1−42, plus a fourth faint band corresponding to Aβ1−39. WB was performed with 6E10 and/or 4G8, using the triplex ELISA, we quantified Aβ1−39, Aβ1−40, and Aβ1−42 in ISF (mean ± SEM: 635 ± 70, 1937 ± 311, and 592 ± 58 pg/ml, respectively; n = 7 mice). Interpolated zero-flow method (mean ± SEM; n = 3–4 mice).

![Figure 1](https://example.com/f1.png)

**Figure 1.** ISF Aβ obtained by microdialysis from behaving 3-month-old J20 hAPP tg mice. a, Rapid decline of ISF Aβ (t1/2 ~ 2 h) upon acute γ-secretase inhibition in vivo in 3-month-old tg (vs wt littermate) mice. ISF sampled hourly at 1 μl/min; Compound E injected at time = 0 h. b, c, ISF collected at 0.2 μl/min were immunoprecipitated with AW8 Aβ antiserum and subjected to two types of SDS-PAGE. b, Conventional SDS-PAGE separates ISF Aβ into a ~4 kDa (monomers (M)) and a ~5 kDa Aβ-immunoreactive (lane 3) species. No dimers (D) were detected in ISF, but can be seen in the TBS-extract of a 24-month-old tg mouse (lane 2) or synthetic (synth.) Aβ (lane 1). WB was performed with 6E10 plus 4G8. c, Bicine/urea SDS-PAGE resolved ISF Aβ into three bands comigrating with synthetic Aβ1−39, Aβ1−40, and Aβ1−42, plus a fourth faint band corresponding to Aβ1−39. WB was performed with 6E10. d, Using 6E10Aβ3-triplex ELISA, we quantified Aβ1−39, Aβ1−40, and Aβ1−42 in ISF (mean ± SEM: 635 ± 70, 1937 ± 311, and 592 ± 58 pg/ml, respectively; n = 7 mice). e, Interpolated zero-flow method (mean ± SEM; n = 3–4 mice).

![Figure 2](https://example.com/f2.png)

**Figure 2.** Amyloid plaques develop and mature with age in J20 APP tg mice without significant changes in full-length (FL) APP or in its proteolytic processing by β- or α-secretases. a, Hippocampal sections from fixed J20 APP tg brain were paraffin-embedded, then stained for Aβ using R1282 polyclonal antibody. Three-month-old tg sections were virtually plaque-free, whereas some plaques had formed by age 12 months. By 24 months, abundant diffuse and dense-core plaques populated the hippocampus. b, Representative blot of brain lysates of 3- and 24-month-old tg mice and wt littermate loaded onto denaturing SDS-PAGE, then blotted for full-length APP and its C-terminal fragments (CTFs) (WB was performed with polyclonal C7) or to α-tubulin (WB was performed with polyclonal α-tubulin-a). c, Summary ratios of immunoreactive signals at 24- versus 3-month-old tg mice, for full-length APP and C-terminal fragments normalized to the α-tubulin signal. n = 3 mice per group; signal quantification by Licor Odyssey.

**Using monoclonal antibody 3D6 (to Aβ1−51 gift from Elan). Proteins were visualized using the Licor Odyssey Infrared Imaging System.**

**Statistical analysis.** Data were analyzed using PRISM (Graphpad Software) for one- or two-way ANOVA, followed by Bonferroni post hoc test if means were significantly different by ANOVA, or Student’s t test, as appropriate.

**ISF Aβ decreases with age as Aβ in brain parenchyma accrues**

To elucidate how amyloid plaque development and maturation affect the steady-state levels of brain ISF Aβ, we sampled ISF from the hippocampal of living J20 tg mice at three ages: preplaque (~3 months), early plaque deposition (~12 months), and abundant and mature plaque deposition (~24 months) (Fig. 2a). The levels
Levels of soluble ISF Aβ <35 kDa in the brain fall with age. a–d, ISF was sampled from the hippocampi of 3- (preplaque), 12- (early plaque deposition), and 24-month old (abundant, mature plaques) J20 tg mice. Using Aβ triple ELISAs, we found that Aβ(38) (a), Aβ(40) (b), and Aβ(42) (c) all decreased with age (means ± SEM; n = 7, 4, 7 mice at 3, 12, and 24 months, respectively). One-way ANOVA, followed by Bonferroni test: *p < 0.05, **p < 0.01, and ***p < 0.001 versus 3 months values; †p < 0.05 versus 12 months values. d, Proportional levels of Aβ(38), Aβ(40), and Aβ(42), where each peptide was normalized to its level at 3 months. Aβ(40) declined the most (80% by 24 months vs 3 months). **p < 0.0001 by two-way ANOVA with age as a variant. 

Table 1. Theoretical concentrations of microdialyzable ISF Aβ in vivo at zero-flow rate

<table>
<thead>
<tr>
<th>ISF Aβ</th>
<th>3 mo</th>
<th>24 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aβ(38) (pg/ml)</td>
<td>930</td>
<td>658</td>
</tr>
<tr>
<td>Aβ(40) (pg/ml)</td>
<td>2975</td>
<td>1231</td>
</tr>
<tr>
<td>Aβ(42) (pg/ml)</td>
<td>880</td>
<td>166</td>
</tr>
<tr>
<td>Aβ(42)-Aβ(40) (pg/ml)</td>
<td>0.30</td>
<td>0.13</td>
</tr>
</tbody>
</table>

Concentrations of endogenous hippocampal ISF Aβ(38), Aβ(40), and Aβ(42) were calculated by extrapolating the curves generated from the interpolated zero-flow method to zero PR (Fig. 5). Ratios of Aβ(42)/Aβ(40) in the ISF of 3- and 24-month-old tg mice were calculated to be ~0.30 and 0.13, respectively, reflecting a higher drop of Aβ(42) versus Aβ(40) in 24-month-old tg mice.

**Figure 3.** Levels of soluble ISF Aβ in vivo at zero-flow rate. Aβ(38), Aβ(40), and Aβ(42) calculated for each mouse and average values of six mice per group. a, Representative IP/WBs of Aβ species from brains of the same mice right after microdialysis, in four pools: ISF, TBS extracted (ext), SDS extracted, and FA extracted. All pools (except FA extracted, which was lyophilized and straight-loaded onto the gel) were immunoprecipitated with AβW and blotted with 6E10 and 4G8. Synthetic (synth.) Aβ1-42 was run alongside for quantification. Perfusion buffer (PB) and TBS were immunoprecipitated as negative controls. b–e, Quantification of IP/WBs from 21 mice shows ~50% decrease in absolute values of ISF Aβ between 3 and 12 months (not significant by one-way ANOVA followed by Bonferroni test) (b), with a sharp rise in TBS- (c), SDS- (d), and FA- (e) extracted Aβ (peaks measured in milligrams wet brain tissue). f, g, Ratios of ISF to TBS-soluble Aβ(42) (f) or to total parenchymal Aβ(42) (g) calculated for each mouse and shown as mean ratio ± SEM; n = 7 mice per group. Aβ(42) quantified by Luminex Odyssey imaging and analyzed by one-way ANOVA and Bonferroni test: **p < 0.001 versus 3 months; †p < 0.05 and ‡p < 0.01 versus 12 months. D, Dimers; M, monomers.

of holoAPP and its C-terminal fragments generated by β- and α-secretases were constant over the 3- to 24-month ISF sampling period (Fig. 2b), suggesting that Aβ production via APP proteolytic processing does not change appreciably over age. As quantified by multiplex Aβ ELISA, all three Aβ peptides measured in ISF (Aβ(38), Aβ(40), and Aβ(42)) decreased over time to levels that were significantly reduced by 24 months (Fig. 3a–c shows absolute values; Fig. 3d shows proportional levels). As the individual peptides fell to different degrees, the Aβ(42)/Aβ(40) ratio in the ISF shifted from 0.3 at 3 months to 0.13 at 24 months. We estimated that the total soluble Aβ concentrations in hippocampal ISF decreased from ~1.2 nM in 3-month-old tg mice to ~0.5 nM in 24-month-old tg mice (for concentrations of individual Aβ peptides in hippocampal ISF of 3- and 24-month-old tg mice, see Table 1). The similar percentage recovery of microdialyzable Aβ at 3 and 24 months (measured at five flow rates) indicates that the age-dependent decrease in ISF Aβ is not due to technical issues with the microdialysis system (Fig. 3e). We measured analytes other than Aβ present in the ISF to see whether they are also altered with age, in particular, lactate, pyruvate, and glycerol. The ratio of lactate to pyruvate is...
An established marker of the redox state of cells; glycerol is an integral component of cellular membranes, and changes in its level can reflect degradation of membranes (Ungerstedt and Rosint, 2004). Neither the lactate-to-pyruvate ratio nor the level of glycerol in ISF changed significantly during our 3–24 months of sampling period (Fig. 3f). Levels were normalized to amounts of each Aβ species before injection. e, Quantification of the individual ISF Aβ peptides in 24-month-old plaque-rich mice for the first 5 h postinjection (means ± SEM, n = 3 mice; p value is by one-way ANOVA). f, Hourly ISF Aβ levels after Compound E injection (0 h) in a 3-month-old plaque-free mouse. Levels were normalized to amounts of Compound E injected via a small cannula attached to the microdialysis probe, into the hippocampal ISF of either age 3–7 months. To better understand the basis for this marked decrease in recovery of diffusible ISF Aβ in the presence of abundant plaques, we approximated the fate of newly secreted Aβ molecules by exogenously administering radiolabeled soluble Aβ. We acutely injected soluble synthetic [125I]Aβ1-40 at a physiological concentration (1 nM), via a small cannula attached to the microdialysis probe, into the hippocampal ISF of either age 3–7 months (plaque-free) or age 24–27 months (plaque-rich). We then measured the ability to recover the radiolabeled peptide from the ISF by microdialysis. From the ISF of the plaque-rich mice, we recovered only 45% of the injected peptide that was recovered from the ISF of plaque-free mice (p < 0.0001) (Fig. 6a). The amounts of the injected [125I]Aβ that were recovered at the two ages correlated well with the respective endogenous Aβ concentrations in the ISF before injection: the [125I]Aβ levels observed in the first hour and the endogenous Aβ levels just before injection were both high in young mice and low in old mice (Fig. 6b), indicating that the acutely injected radiopeptide achieves a similar equilibrium as the endogenous Aβ has at steady state. We hypothesized that in plaque-rich mice, the acutely administered monomer is more readily incorporated into their abundant Aβ deposits and thus is less recoverable in the ISF. To address this idea, we quantified the radioactivity retained in the TBS extracts of brain. We saw a substantially
higher amount of the fresh, exogenous radiopeptide retained in the TBS extracts of the older mice (Fig. 6c). In the short time frame we conducted these analyses (i.e., the first 90 min after administration), we did not detect significant levels of radioactivity in the SDS and FA fractions. Together, these results suggest that in plaque-burdened mice, newly generated soluble Aβ released into the ISF readily accrues onto parenchymal deposits, accounting for its lower steady-state level in the ISF.

The level of ISF Aβ42 in plaque-rich mice is minimally affected by acute γ-secretase inhibition

To assess whether the ISF Aβ we measured in plaque-rich older mice also represents recent APP cleavage products, as we had determined in young mice (Fig. 1a), we acutely inhibited γ-secretase in vivo with Compound E. There was a rapid decline of Aβ38 and Aβ40 (~60% fall in the first 3 h; t1/2, ~1.9 h and ~2.3 h, respectively), whereas Aβ42 declined significantly less (~20% fall) (Fig. 6d,c). In contrast, all three peptides fell together in young plaque-free mice during the first 5 h after shutting down new production with Compound E (Fig. 6f). As Aβ42 is the species reported to accumulate much more into plaques than the other, more abundantly generated Aβ peptides in both AD patients and APP mice (Iwatsubo et al., 1994; Johnson-Wood et al., 1997), these results suggest that most of the soluble Aβ42 peptide that populates the ISF pool in plaque-rich mice is not derived primarily from new Aβ biosynthesis but rather from the large reservoir of less soluble Aβ42 in the brain parenchyma. The results also indicate that acute γ-secretase inhibition is less effective in lowering Aβ42 in plaque-rich brains.

Saline-extractable Aβ of brain parenchyma in its native form appears to exist principally in assemblies >500 kDa

Bicine/urea SDS-PAGE gels showed that the Aβ peptide distribution differed between the ISF and TBS-extracted pools at all ages (Fig. 7a). Even at age 3 months, when the brain has virtually no plaques, Aβ40 was the primary Aβ species in ISF, while, in the TBS-extracted pool, Aβ42 was already the more abundant peptide at steady state, despite the fact that it is generated in much lower amounts than Aβ40 (Fig. 7a). Accordingly, the Aβ42/Aβ40 ratio differed markedly between the ISF (low ratio) and TBS extract (very high ratio) (Fig. 7b). This stark difference led us to question the general assumption that the brain Aβ pool that comes into solution upon mechanical homogenization in physiological buffers represents the truly soluble pool (McLean et al., 1999; Walsh and Selkoe, 2004; Shankar et al., 2009). We performed non-denaturing SEC on the TBS extract and subjected the resultant SEC fractions to SDS-PAGE for WB analysis. Surprisingly, most Aβ in the TBS extracts of plaque-free (3 months tg) mice eluted in the void volume of a Superdex 200 SEC column [suggesting a molecular weight (MW) >500 kDa], and this material ran principally as monomers when electrophoresed on a denaturing gel (Fig. 7c, fractions 6 and 7). The SEC elution profiles of TBS extracts from 3- and 24-month-old tg mice were similar and differed sharply from that of synthetic Aβ42 peptide alone (Fig. 7c). In accordance with this, Aβ in TBS extracts from 24-month-old tg mice ran as an aggregated, high MW complex.
MW A subsequent denaturation in LDS sample buffer yielded lower peptide. Moreover, a reduced CSF level of A potently to the pathogenesis of AD (Pimplikar et al., 2010), most importantly under development (A processing (A factors contribute to steady-state A levels in brain ISF. There is a constant supply of A in vivo). In humans, CSF levels of A, appear to relate inversely to amyloid plaque burden, degree of brain atrophy, and severity of cognitive deficits in humans (Motter et al., 1995; Fagan et al., 2009; Shaw et al., 2009). Our dynamic studies of the change in endogenous ISF A and of the fate of radiolabeled A before versus after plaque initiation offer strong evidence from controlled animal experiments for the hypothesis that soluble A in humans falls in the CSF because it is sequestered into increasingly insoluble parenchymal deposits as AD develops.

What are the driving forces leading to the sharp decline of diffusible A species as AD-like pathology progresses with age? The constant levels of both full-length APP and the C-terminal fragments generated by α- and β-secretases suggest that the fall we observe is not due to a decrease of cellular production of A. We also saw no evidence for a perturbation of cell membrane integrity, a change in an indicator of intermediary metabolism, or altered spontaneous behavior (eating, exploring, grooming, etc.) in the mice, arguing against general cytotoxicity or cell death as an explanation for the drop. Thus, we obtained no evidence that decreased neuronal activity or decreased A production explains the drop in soluble ISF A as mice accrue amyloid deposits. Rather, the decrease in ISF A occurred simultaneously with rises of insoluble A in the SDS- and FA-extractable pools (Figs. 3, 4). Furthermore, the distinct dispositions of soluble radiolabeled A injected at physiologic concentrations directly into the ISF in plaque-free versus plaque-rich animals provide insight into a shift in A economy of soluble A in vivo; see Fig. 4 from the same mice did not rise until 24 months and then only very slightly. Values are means ± SEM from Figures 3 and 4.

![Diagram of Aβ dynamics](image)

**Figure 8.** Summary of the temporal changes in the four Aβ brain pools. **a.** Decreases with age in all three in vivo ISF Aβ peptides measured by 6E10 Aβ triplex sandwich ELISA (for details, see Fig. 3). **b.** The fold-decrease measured by ELISA (significant between ages 3 and 24 months by two-way ANOVA; see Fig. 2) is comparable to the fold-decrease measured by IP/WB (though the latter was not significant by one-way ANOVA; for details, see Fig. 4). The total amount measured by IP/WB analysis method was only ~30% of the total amount measured by ELISA. **c.** IP/WB analysis of Aβ in brain tissue. By ~24 months, there was a steep increase in insoluble (SDS- and FA-extractable) Aβ. The TBS-extracted Aβ from the same mice did not rise until 24 months and then only very slightly. Values are means ± SEM from Figures 3 and 4.

**Discussion**

Although factors other than Aβ dyshomeostasis contribute importantly to the pathogenesis of AD (Pimplikar et al., 2010), most potentially disease-modifying treatments currently under development are focused on decreasing or neutralizing this neurotoxic peptide. Moreover, a reduced CSF level of Aβ42 in subjects with incipient or very early AD is one of the most promising biomarkers. Despite this therapeutic and diagnostic focus, we still lack insight into the in vivo economy of soluble Aβ in the brain as AD-type pathology forms. Here, we used the powerful method of brain microdialysis in awake, behaving hAPP transgenic mice to gain understanding of the dynamics of the most soluble forms of Aβ in the hippocampus before and during the process of Aβ plaque formation. Our results show that Aβ peptides, which remain soluble and of low molecular weight in the interstitial fluid in vivo, decrease significantly—both absolutely (Figs. 3–5, 7a) and especially in relation to the soluble Aβ extractable from brain membranes (Fig. 4d)—as plaques accumulate. Aβ42 decreases the most among the three major Aβ peptides in the ISF; in agreement with this, Aβ40 rises the most in the less soluble Aβ pools in the brain parenchyma (Figs. 3, 7a), keeping with its documented primary role in oligomerization and plaque formation. Figure 8 provides summaries of the temporal changes documented in this study.

Of special clinical relevance is that our discovery of an age-dependent decrease in ISF Aβ42 may be analogous to the widely documented selective decrease in soluble Aβ42 in human (AD) CSF (Motter et al., 1995). In humans, CSF levels of Aβ42 appear to relate inversely to amyloid plaque burden, degree of brain atrophy, and severity of cognitive deficits in humans (Motter et al., 1995; Fagan et al., 2009; Shaw et al., 2009). Our dynamic studies of the change in endogenous ISF Aβ and of the fate of radiolabeled Aβ before versus after plaque initiation offer strong evidence from controlled animal experiments for the hypothesis that soluble Aβ42 in humans falls in the CSF because it is sequestered into increasingly insoluble parenchymal deposits as AD develops.

![Diagram of Aβ dynamics](image)

**Figure 9.** A hypothetical model of Aβ in vivo dynamics before versus after plaque formation based on data herein. Several factors contribute to steady-state Aβ levels in brain ISF. There is a constant supply of Aβ in the ISF pool generated by new APP processing (Aβ42 >> Aβ40 >> Aβ38 >> Aβ39), and this generation appears to change little with age. ISF Aβ can be proteolytically degraded, cleared locally by glia and/or transported across the blood brain barrier (BBB). Soluble Aβ starts aggregating at an early age in brain parenchyma, as evidenced by the >500 kDa TBS-extractable pool as well as an SDS-extractable pool in 3-month-old plaque-free mice. The most abundant pools in a plaque-free brain are the ISF pool and the SDS-extractable pool. In a plaque-rich brain, however, equilibrium between pools is greatly altered by the overwhelming amount of aggregated Aβ, which act as a sink, thereby diminishing the steady-state ISF pool. Plaques may also act as a contributor to the ISF pool, where Aβ42, the most abundant peptide in plaques (and also the most decreased in the ISF) diffuses back into the ISF. HMW, High MW (i.e., >500 kDa).
ing to decreased recovery during microdialysis, consistent with a report of lengthened Aβ clearance time in old versus young APP transgenic mice (Cirrito et al., 2003).

Indirect evidence for a converse pathway suggests that such membrane association is not irreversible. Our finding that upon acute γ-secretase inhibition there was significantly less fall in ISF, specifically of Aβ_{42} (which is much more abundant in plaques), suggests that plaques contribute to a dynamic equilibrium between soluble and insoluble Aβ_{42} pools in the brain and thus help regulate the steady state of ISF Aβ in aged mice (for a model, see Fig. 9). This concept is consistent with evidence that amyloid plaques in APP transgenic mice appear to act as a local reservoir of loosely associated Aβ that can diffuse from plaques and populate a halo of oligomeric and monomeric Aβ immediately surrounding the amyloid core (Spire et al., 2005; Koffie et al., 2009).

It will be interesting to see whether acute alteration of one particular Aβ pool (e.g., via agents such as antibodies that can selectively bind aggregated Aβ or agents that only sequester the fully soluble ISF pool) will have transient or lasting effects on the equilibrium maintained among the Aβ pools.

Aβ in aqueous extracts of homogenized cerebral cortex has been termed by our group and others as the “soluble Aβ pool” and is thought to be derived from ISF and cytosol, not necessarily from particulates such as amyloid deposits (Gravina et al., 1995; Lue et al., 1999; McLean et al., 1999; Walsh and Selkoe, 2004; Shankar et al., 2009); the rise in this pool was thought to reflect a rise in diffusible Aβ in vivo. However, we show here that Aβ peptides in aqueous parenchymal extracts differ significantly in quality and quantity from those that remain of low MW in the ISF pool. Furthermore, using non-denaturing SEC and native gels, we show that much native Aβ in the TBS extracts of APP transgenic mouse brains, even at a preplaque age of 3 months, exists in assemblies >500 kDa, extending similar data on the aqueous extracts of AD brains (Shankar et al., 2008). Thus, aqueous extracts of Aβ may principally reflect aggregated Aβ peptides bound to cell membranes (in young mice) and to membranes and plaques (in older mice) but which remain water-extractable.

Given this new understanding that aqueous extracts of brain may not reflect the truly diffusible Aβ species in vivo, it will be important to examine the nature of synaptotoxicity in the different Aβ pools, including the ISF pool and the TBS-extracted pool, which is currently thought to principally contain the toxic oligomeric species. Interestingly, we have not detected SDS-stable dimers in any of our ISF microdialyses to date, which could be due in part to the limits of detection. Using a test tube model of our microdialysis technique, we found that synthetic Aβ dimers (~8 kDa) crossed over the 35 kDa MWCO membrane; however, the diffusion efficiency of dimers was poor compared with that of monomers (data not shown). Therefore, we cannot exclude the existence of low levels of soluble dimers in the ISF of hAPP transgenic mice. Our results may instead suggest that soluble dimers and other oligomers do not actually exist per se in the most dif-

fusible brain pool (ISF); rather, newly formed oligomers (with their exposed hydrophobic amino acids) may distribute quickly onto hydrophobic surfaces (cell membranes and/or amyloid deposits).

As regards the implications of our findings for the pathophysiology of AD, it will be important in future studies to attempt to detect any bioactivity of the ISF Aβ pool at the different plaque stages of APP transgenic mice. Whereas the ISF of young, plaque-free mice acts as a reservoir mainly for the acute cellular production of Aβ, ISF in plaque-rich mice seems to be a reservoir for both new Aβ production and Aβ that diffuses from membrane-and plaque-bound deposits (as evidenced by the finding that ISF Aβ_{42} levels do not fall significantly upon acute inhibition of γ-secretase). Whether the Aβ_{42} that comes off of parenchymal deposits into the ISF is pathogenically important (compared with Aβ in the ISF of plaque-free brains) will be important to determine.

In conclusion, these dynamic analyses provide unique insights into the generation of first fully soluble and then increasingly less soluble Aβ species during age-related accrual of AD-type amyloid deposits in living animals. Based on the usefulness of these pre-clinical data, we suggest a provocative approach toward potentially extending such studies to humans. Patients with normal pressure hydrocephalus (NPH), which is typified by a clinical triad of subacutely developing dementia, incontinence, and gait ataxia (Relkin et al., 2005; Shprecher et al., 2008), are frequently offered a neurosurgical procedure by which a ventriculoperitoneal shunt is inserted to chronically drain the excess ventricular CSF to the peritoneal cavity and thus potentially improve the patients’ NPH symptoms. Several studies of simultaneously obtained cortical biopsies have shown that some or many such shunted patients show amyloid plaques and neurofibrillary tangles indistinguishable from those in typical AD patients (Del Bigio et al., 1997; Bech et al., 1999; Golomb et al., 2000; Hamilton et al., 2010). This co-occurrence suggests that obtaining institutional review board approval to perform a brief (12–24 h) placement of a microdialysis probe at the time of an NPH shunt placement could enable in vivo analysis of ISF Aβ peptides in humans with varying degrees of Aβ deposition. We propose that such controlled clinical research studies in appropriate patients be considered to obtain direct information about the economy of the most soluble species of brain Aβ (those in ISF) as a function of the level of cerebral β-amyloidosis in humans.

References


